Genentech is informing its customers and distributors and is arranging for return of all impacted products. Genentech announced a voluntary recall of three lots of Activase (alteplase) 100mg vials ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Despite concerns ...

PURPOSE: To evaluate the safety and efficacy of alteplase (TPA) for restoring function to occluded central venous catheters (CVCs). PATIENTS AND METHODS: The study design was a phase III, open-label, ...

April 15, 2004 -- Alteplase (tissue plasminogen activator; TPA) is the least expensive thrombolytic therapy for deep vein thrombosis (DVT), according to the results of a retrospective review published ...

Patients with stroke who receive intra-arterial thrombolysis after thrombectomy are more likely to achieve superior 90-day ...

A noninferiority trial comparing two doses of thrombolytic therapy with the tissue plasminogen activator (tPA) alteplase has failed to demonstrate that low-dose therapy is as effective as ...

Recent use of direct oral anticoagulants (DOACs) does not seem to be associated with increased risk of intracranial hemorrhage among patients with acute ischemic stroke treated with intravenous ...

Roche’s subsidiary, Genentech, issued the voluntary recall of the anti-stroke drug because of compromised vials containing sterile water that were packaged with the drug. Roche’s Genentech is ...

In a meta-analysis presented at the European Stroke Organization Conference, alteplase was more effective than placebo for treatment of acute ischemic stroke between 4.5 and 9 hours after onset.

Ross McC. Lilley and Archie R. Portis, Jr. The ATPase activity and fluorescence of ribulose-1,5-bisphosphate carboxylase oxygenase (Rubisco) activase were determined over a range of MgCl2, KCl, and ...